THU0233 Myopathy is a poor prognostic feature in systemic sclerosis. Results from the canadian scleroderma research group (CSRG) cohort. (23rd January 2014)
- Record Type:
- Journal Article
- Title:
- THU0233 Myopathy is a poor prognostic feature in systemic sclerosis. Results from the canadian scleroderma research group (CSRG) cohort. (23rd January 2014)
- Main Title:
- THU0233 Myopathy is a poor prognostic feature in systemic sclerosis. Results from the canadian scleroderma research group (CSRG) cohort
- Authors:
- Jung, M.
Baron, M.
Hudson, M.
Bonner, A.
Pope, J.E. - Abstract:
- Abstract : Background: Myopathy/myositis is associated with more severe systemic scleroderma (SSc). Objectives: The aim of this study was to determine such clinical information from the Canadian Scleroderma Research Group database (CSRG). Methods: Data from the CSRG are collected annually on SSc patients. Two surrogate markers for myopathy used in this study were elevated creatine kinase (CK) and physician-reported history of myopathy/myositis of the patients. Comparisons were made between those with and without myopathy/myositis to determine the strongest associations with this complication; overall, in lcSSc and dcSSc and in early dcSSc subset. Survival with and without myopathy/myositis was determined. Results: The study included 1143 patients with mean of 8 years of duration. Elevated CK occurred in 5.6%; 9.7% had a history of inflammatory myositis or myopathy according to physician; 5.7% had proximal muscle weakness. Those with elevated CK compared to remainder were more likely to be male (24.5% in elevated CK vs. 12.6% in normal CK; p<0.013), younger (51.93 vs. 56.07 years, p<0.045); have dcSSc, (40.4% vs. 37.9%; p<0.002), physician-reported history of myositis/myopathy (45.3% vs. 8.5%, p<0.000), tendon friction rubs (30.0% vs. 13.4%; p<0.001), FVC <70% (23.9% vs. 13.1%; p<0.039), RNP antibody (12.0% vs. 5.0%, p<0.032), Topo1 antibody (26.0% vs. 14.4%, p<0.026), higher skin scores (MRSS 16.14 vs. 9.81; p<0.000), and higher HAQ score (0.98 vs. 0.79; p<0.011). When usingAbstract : Background: Myopathy/myositis is associated with more severe systemic scleroderma (SSc). Objectives: The aim of this study was to determine such clinical information from the Canadian Scleroderma Research Group database (CSRG). Methods: Data from the CSRG are collected annually on SSc patients. Two surrogate markers for myopathy used in this study were elevated creatine kinase (CK) and physician-reported history of myopathy/myositis of the patients. Comparisons were made between those with and without myopathy/myositis to determine the strongest associations with this complication; overall, in lcSSc and dcSSc and in early dcSSc subset. Survival with and without myopathy/myositis was determined. Results: The study included 1143 patients with mean of 8 years of duration. Elevated CK occurred in 5.6%; 9.7% had a history of inflammatory myositis or myopathy according to physician; 5.7% had proximal muscle weakness. Those with elevated CK compared to remainder were more likely to be male (24.5% in elevated CK vs. 12.6% in normal CK; p<0.013), younger (51.93 vs. 56.07 years, p<0.045); have dcSSc, (40.4% vs. 37.9%; p<0.002), physician-reported history of myositis/myopathy (45.3% vs. 8.5%, p<0.000), tendon friction rubs (30.0% vs. 13.4%; p<0.001), FVC <70% (23.9% vs. 13.1%; p<0.039), RNP antibody (12.0% vs. 5.0%, p<0.032), Topo1 antibody (26.0% vs. 14.4%, p<0.026), higher skin scores (MRSS 16.14 vs. 9.81; p<0.000), and higher HAQ score (0.98 vs. 0.79; p<0.011). When using logistic regression younger age male, dcSSc, early dcSSc, tendon friction rubs, higher MRSS, Topo1, RNP, PMScl, and FVC<70% were associated with elevated CK. Survival was less in those with myopathy/myositis or elevated CK (p=0.003 and p=0.025 respectively). Those with elevated CK had less survival (p=0.025). Results were similar when the other definition of myopathy/myositis. Conclusions: Myopathy/myositis has a worse prognosis with respect to function and other organ involvement (ILD) and survival. Disclosure of Interest: M. Jung: None Declared, M. Baron: None Declared, M. Hudson: None Declared, A. Bonner: None Declared, J. Pope Grant/Research support from: Research support from CIHR, Scleroderma Society of Canada, Scleroderma Society of Ontario … (more)
- Is Part Of:
- Annals of the rheumatic diseases. Volume 71(2012)Supplement 3
- Journal:
- Annals of the rheumatic diseases
- Issue:
- Volume 71(2012)Supplement 3
- Issue Display:
- Volume 71, Issue 3 (2012)
- Year:
- 2012
- Volume:
- 71
- Issue:
- 3
- Issue Sort Value:
- 2012-0071-0003-0000
- Page Start:
- 234
- Page End:
- 234
- Publication Date:
- 2014-01-23
- Subjects:
- Rheumatism -- Periodicals
616.723005 - Journal URLs:
- http://ard.bmjjournals.com/ ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=149&action=archive ↗
http://www.bmj.com/archive ↗
http://gateway.ovid.com/server3/ovidweb.cgi?T=JS&MODE=ovid&D=ovft&PAGE=titles&SEARCH=annals+of+the+rheumatic+diseases.tj&NEWS=N ↗ - DOI:
- 10.1136/annrheumdis-2012-eular.2198 ↗
- Languages:
- English
- ISSNs:
- 0003-4967
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 18361.xml